Our ongoing global Phase 2 clinical trial for #ARDS will be presented at the International Symposium on Intensive Care and Emergency Medicine (#ISICEM) conference in Brussels, Belgium on March 19, 2025. Dr. Arthur Van Zanten,?Head of ICU & Research and Professor at Wageningen University & Research Netherlands,?will be presenting,?“A Place for Gelsolin Administration.” Our CEO Susan Levinson, PhD and Chief Medical Officer Howard Levy,?MD PhD MMM, will be attending this key critical care conference. COO Valerie Ceva will present,?“Conquering Diseases Driven by Excess Inflammation,”?at the MedInvest Conferences Biotech & Pharma Investor Conference in NYC on March 27, 2025. #gelsolin #biotechinvesting #clinicaltrials, #criticalcare #lungs #lungdamage?#inflammatorydiseases #NLRP3inflammasome #respiratoryfailure #savinglives
BioAegis Therapeutics, Inc.
生物技术研究
North Brunswick，New Jersey 2,204 位关注者
Commercializing a key component of the immune system, #Gelsolin, for infectious, inflammatory and degenerative diseases.
关于我们
Commercializing Ground Breaking Discoveries in Inflammation and Infection BioAegis Therapeutics products restore plasma gelsolin, a human protein, whose important clinical role has been studied in animals and humans. Based on discoveries by Dr. Thomas Stossel and others, the body’s natural reservoir of plasma gelsolin keeps inflammation local, while its deficiency leads to inflammatory dysregulation and catastrophic consequences like multiple organ failure, shock and death. Systemic inflammation causes morbidity and mortality in a myriad of diseases including rare orphan indications and major acute and chronic diseases such as trauma, burns, renal disease and sepsis. Replacement of plasma gelsolin holds great promise for patients suffering from severe conditions with high unmet medical needs. BioAegis is developing high value, biomarker-directed treatments across a range of indications.
- 网站
-
https://www.bioaegistherapeutics.com
BioAegis Therapeutics, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- North Brunswick，New Jersey
- 类型
- 私人持股
- 创立
- 2011
地点
-
获取路线
675 US Route 1
US，New Jersey，North Brunswick，08902
BioAegis Therapeutics, Inc.员工
动态
-
BioAegis Therapeutics, Inc.转发了
Exciting Clinical Trial Update! - Over 23 sites in 7 countries are live -- and increasing daily. - First patients have been enrolled in both Europe and the US. BioAegis is making big strides with our groundbreaking?600-person global phase 2 clinical trial?of recombinant human plasma gelsolin (rhu-pGSN) for moderate to severe?Acute Respiratory Distress Syndrome (#ARDS). ARDS is a life threatening lung condition with a 40% mortality rate, yet there are no approved pharmacological treatments for this deadly condition. The lack of effective therapies to treat ARDS and its associated high mortality driven by excess #inflammation underscores the urgent need for an innovative therapy in this field. #Gelsolin, a naturally occurring #immunesystem protein, is a master regulator of inflammation. It is depleted by counteracting the inflammatory process. Supplementation with the recombinant gelsolin protein (rhu-pGSN) holds promise to address the inflammatory response associated with ARDS. #BioAegis, #clinicaltrials, #lungs, #lungdamage??#respiratoryfailure #savinglives #biotechinvesting #biotech ARDS Alliance Valerie Ceva Susan Levinson Steven Cordovano
-
-
Exciting Clinical Trial Update! - Over 23 sites in 7 countries are live -- and increasing daily. - First patients have been enrolled in both Europe and the US. BioAegis is making big strides with our groundbreaking?600-person global phase 2 clinical trial?of recombinant human plasma gelsolin (rhu-pGSN) for moderate to severe?Acute Respiratory Distress Syndrome (#ARDS). ARDS is a life threatening lung condition with a 40% mortality rate, yet there are no approved pharmacological treatments for this deadly condition. The lack of effective therapies to treat ARDS and its associated high mortality driven by excess #inflammation underscores the urgent need for an innovative therapy in this field. #Gelsolin, a naturally occurring #immunesystem protein, is a master regulator of inflammation. It is depleted by counteracting the inflammatory process. Supplementation with the recombinant gelsolin protein (rhu-pGSN) holds promise to address the inflammatory response associated with ARDS. #BioAegis, #clinicaltrials, #lungs, #lungdamage??#respiratoryfailure #savinglives #biotechinvesting #biotech ARDS Alliance Valerie Ceva Susan Levinson Steven Cordovano
-
-
Our CEO, Susan Levinson, with be a panelist at the 7th Annual Symposium for Life Science Innovation and Development, where she will share BioAegis' progress and our journey at the NJ BioScience Center. #LifeSciences #Innovation #BioAegis #biotech #biotechfunding #savinglives #NewJersey #NJstrong BioNJ New Jersey Economic Development Authority (NJEDA)
New Jersey is a powerhouse in the life sciences sector, with over 19 million square feet of space dedicated to cutting-edge biopharma innovation. While the state remains home to big pharma, many former pharma properties have been repurposed for multi-tenant use, fueling growth for emerging life sciences companies across the Greater NY Metro area. These research parks are the growth engines driving the future of the region’s life sciences economy. Join us for a deep dive into the progress of these research hubs with industry leaders John Pena, MD, PhD, CEO of Sonder RX; Susan Levinson, PhD, CEO of BioAegis Therapeutics, Inc.; and Matthew P. Flath, Senior VP Asset at Onyx Equities. Moderated by Lenzie Harcum, Director of New Jersey Bioscience Center / Incubator at North Brunswick, this panel will explore the latest in life sciences innovation, collaboration, and development within New Jersey’s vibrant research parks. Don’t miss out on this opportunity to hear firsthand from the leaders shaping the future of biopharma! View the agenda and register today!?https://lnkd.in/eaSSwDFU ? Interested in reaching hundreds of stakeholders in the life science community? Sponsorship packages, program ads, and exhibit booths are still available:??https://lnkd.in/epUsYxJY #NYMetroBuildsBio #NYMSymposium #LifeSciences #ResearchParks #EconomicDevelopment #EmergingBiotech
-
-
A sad loss of a kind man, so generous of his time in pursuing science for patients.
It’s with a heavy heart that I share the news that our dear colleague Dr. John Gallin has passed away. He was the longest-serving director of the NIH Clinical Center (CC). With a 50+ year career at NIH, he leaves an incredible legacy that lives on in the important work at the NIH Clinical Center and in generations of clinician-scientists. I extend my deepest condolences to his family, friends, and colleagues.?https://lnkd.in/eXx3r9JT
-
-
Our team at #BioAegis is saddened to hear of Dr. Gallin's passing.?He was a passionate researcher seeking solutions for patients and we were privileged to collaborate with him and his colleagues on studies in Covid-19 and chronic granulomatous disease (CGD). Deepest condolences from the BioAegis family to his.
It’s with a heavy heart that I share the news that our dear colleague Dr. John Gallin has passed away. He was the longest-serving director of the NIH Clinical Center (CC). With a 50+ year career at NIH, he leaves an incredible legacy that lives on in the important work at the NIH Clinical Center and in generations of clinician-scientists. I extend my deepest condolences to his family, friends, and colleagues.?https://lnkd.in/eXx3r9JT
-
-
Major Milestone – 1st?Patient enrolled in our clinical study. Our $20M contract with?Biomedical Advanced Research and Development Authority (#BARDA)?Division of?Research,?Innovation, and?Ventures (DRIVe) supports the execution of?this major phase 2b global?study of recombinant?human?plasma?#gelsolin (rhu-pGSN)?for?moderate-to-severe?ARDS. The study is being conducted at 75 sites in 13 countries. Enrollment is targeted at 600 patients. ARDS affects over 500,000 patients in the US per year or roughly 10% of all ICU admissions. The mortality rate for ARDS is approximately 40%, yet there are no approved medications for it.? #Gelsolin, a naturally occurring #immunesystem protein, is a master regulator #inflammation. It is depleted by counteracting the inflammatory process. Supplementation with the recombinant gelsolin protein (rhu-pGSN) holds promise to address the inflammatory response associated with ARDS. Susan Levinson Valerie Ceva Steven Cordovano ARDS Alliance #BioAegis, #immunotherapy #NLRP3inflammasome?#immunesystem #hostdirected #clinicaltrials, #lungs, #lungdamage??#respiratoryfailure #savinglives
-
Announcing four US clinical tial sites are now live! BioAegis is conducting a 600 patient Phase 2b global?study of recombinant human?plasma?gelsolin (rhu-pGSN)?for?moderate-to-severe?Acute Respiratory Distress Syndrome (ARDS) ARDS affects over 500,000 patients in the US per year or roughly 10% of all ICU admissions. The mortality rate for ARDS is approximately 40%. The lack of effective therapies to treat ARDS and its associated high mortality driven by excess #inflammation underscores the urgent need for an innovative therapy in this field. #Gelsolin, a naturally occurring #immunesystem protein, is a master regulator inflammation. It is depleted by counteracting the inflammatory process. Supplementation with the recombinant gelsolin protein (rhu-pGSN) holds promise to address the inflammatory response associated with ARDS. "ARDS is significant source of mortality as well as a drain on healthcare resources across the globe. We are committed to reaching our goal of saving lives by addressing the challenges of this complex disease,"?stated?Susan Levinson, Ph.D., Chief Executive Officer of BioAegis. #gelsolin, #ARDS, #clinicaltrials, #lungs, #lungdamage???#respiratoryfailure #savinglives #sepsis #pneumonia #covid19
-
-
21,156 vials ready for our clinical trial! #BioAegis is conducting a major global Phase 2 study of #gelsolin for the treatment of patients with moderate to severe Acute Respiratory Distress Syndrome (#ARDS). Enrollment is targeted at 600 patients in 13 counties. ARDS, a life threatening lung condition, has a 40% mortality rate, yet there are NO approved medications for this deadly condition. Our lead product, #rhu-pGSN, is the recombinant form of plasma gelsolin, a naturally occurring #immunesystem protein and master regulator of inflammation. Gelsolin is depleted in the body when counteracting the inflammatory process. Supplementation with the recombinant gelsolin protein (rhu-pGSN) holds much promise to address the extreme inflammatory response associated with ARDS. #BioAegis, #gelsolin, #ARDS, #clinicaltrials, #lungs, #lungdamage???#respiratoryfailure #savinglives
-